全球医药行业的最新风向标,也就是这件事了

锦缎研究院
Nov 07

本文系基于公开资料撰写,仅作为信息交流之用,不构成任何投资建议为了争夺GLP-1减肥药开发商Metsera,辉瑞与诺和诺德正争得不可开交。全球医药行业的最新风向标,也就是这件事了。9月21日,辉瑞已经与Metsera签署《合并协议与计划》,以49亿美元现金及24亿美元里程碑付款的对价进行收购。这项收购原本只差监管部门的同意,但诺和诺德却突然横插一脚。为了得到Metsera,诺和诺德先是在10月底...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10